Carrot's GreenMan acquisition adds cataract lens simulation, backed by a 609-patient study, as VR eye-care technology expands beyond diagnostics.
Genentech's vamikibart sustained vision gains at 52 weeks, but mixed Phase III results leave questions ahead of a July 2027 FDA decision.
Merck's remigromig met BRUNELLO's vision endpoint, but higher retinal complication rates complicate its potential in diabetic macular edema.
Haag-Streit launches Octopus 910 in the US with automated glaucoma testing and HFA data import. Can it improve clinical workflows?